CVS Health (NYSE:CVS - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect CVS Health to post earnings of $1.62 per share and revenue of $93.07 billion for the quarter. CVS Health has set its FY 2025 guidance at 5.750-6.000 EPS.
CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, analysts expect CVS Health to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
CVS Health Stock Down 0.1 %
NYSE:CVS traded down $0.09 during trading hours on Tuesday, hitting $64.84. 1,466,620 shares of the company traded hands, compared to its average volume of 11,784,960. CVS Health has a one year low of $43.56 and a one year high of $71.45. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a market cap of $81.75 billion, a PE ratio of 17.73, a PEG ratio of 0.98 and a beta of 0.57. The firm's 50-day simple moving average is $66.45 and its 200-day simple moving average is $58.75.
CVS Health Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be given a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 annualized dividend and a yield of 4.10%. CVS Health's dividend payout ratio is currently 72.68%.
Analysts Set New Price Targets
Several research firms recently commented on CVS. Robert W. Baird upped their price objective on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research note on Tuesday, April 15th. Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Truist Financial boosted their price objective on CVS Health from $76.00 to $82.00 and gave the stock a "buy" rating in a report on Friday, April 11th. Cantor Fitzgerald upgraded CVS Health from a "neutral" rating to an "overweight" rating in a research report on Wednesday, February 12th. Finally, Evercore ISI upped their price objective on shares of CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Monday, January 27th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and an average target price of $71.83.
Get Our Latest Stock Report on CVS
Insider Transactions at CVS Health
In other CVS Health news, Director Michael F. Mahoney purchased 30,000 shares of the stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP James David Clark sold 7,513 shares of CVS Health stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.22% of the company's stock.
About CVS Health
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
